IE44387B1 - Delayed-action hypotensive pharmaceutical compositions - Google Patents
Delayed-action hypotensive pharmaceutical compositionsInfo
- Publication number
- IE44387B1 IE44387B1 IE2088/76A IE208876A IE44387B1 IE 44387 B1 IE44387 B1 IE 44387B1 IE 2088/76 A IE2088/76 A IE 2088/76A IE 208876 A IE208876 A IE 208876A IE 44387 B1 IE44387 B1 IE 44387B1
- Authority
- IE
- Ireland
- Prior art keywords
- compositions
- diol
- amino
- dichlorobenzylidene
- hydroxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 230000001077 hypotensive effect Effects 0.000 title claims abstract description 8
- 208000001953 Hypotension Diseases 0.000 title claims abstract description 5
- 208000021822 hypotensive Diseases 0.000 title claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 10
- 239000000194 fatty acid Substances 0.000 claims abstract description 10
- 229930195729 fatty acid Natural products 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 7
- QKIQJNNDIWGVEH-UHFFFAOYSA-N guanoxabenz Chemical compound ONC(=N)NN=CC1=C(Cl)C=CC=C1Cl QKIQJNNDIWGVEH-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 36
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- IHEJEKZAKSNRLY-UHFFFAOYSA-N nonacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O IHEJEKZAKSNRLY-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- PQPZROSFRCBPIM-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methylideneamino]-1-hydroxyguanidine;hydron;chloride Chemical compound Cl.ONC(N)=NN=CC1=C(Cl)C=CC=C1Cl PQPZROSFRCBPIM-UHFFFAOYSA-N 0.000 claims description 6
- 150000002009 diols Chemical class 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- VXZBFBRLRNDJCS-UHFFFAOYSA-N heptacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VXZBFBRLRNDJCS-UHFFFAOYSA-N 0.000 claims description 4
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000008119 colloidal silica Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000037849 arterial hypertension Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000001089 Multiple system atrophy Diseases 0.000 description 3
- 206010031127 Orthostatic hypotension Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WFBHRSAKANVBKH-UHFFFAOYSA-N N-hydroxyguanidine Chemical compound NC(=N)NO WFBHRSAKANVBKH-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- CKDDRHZIAZRDBW-UHFFFAOYSA-N henicosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC(O)=O CKDDRHZIAZRDBW-UHFFFAOYSA-N 0.000 description 2
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- MWMPEAHGUXCSMY-UHFFFAOYSA-N pentacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O MWMPEAHGUXCSMY-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- XEZVDURJDFGERA-UHFFFAOYSA-N tricosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)=O XEZVDURJDFGERA-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- NLURKIGXJGGBOJ-UHFFFAOYSA-N 2-hydroxyguanidine;hydrochloride Chemical compound Cl.NC(N)=NO NLURKIGXJGGBOJ-UHFFFAOYSA-N 0.000 description 1
- SDEBYHVDMCQKNZ-UHFFFAOYSA-N 4-methoxy-6-piperazin-1-ylpyrimidine;hydrochloride Chemical compound Cl.C1=NC(OC)=CC(N2CCNCC2)=N1 SDEBYHVDMCQKNZ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- KFEVDPWXEVUUMW-UHFFFAOYSA-N docosanoic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 KFEVDPWXEVUUMW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7528940A FR2324294A1 (fr) | 1975-09-22 | 1975-09-22 | Nouveau medicament hypotenseur a action retardee, ainsi que le procede de preparation de ce nouveau medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE44387L IE44387L (en) | 1977-03-22 |
| IE44387B1 true IE44387B1 (en) | 1981-11-18 |
Family
ID=9160270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2088/76A IE44387B1 (en) | 1975-09-22 | 1976-09-21 | Delayed-action hypotensive pharmaceutical compositions |
Country Status (14)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8148429B2 (en) | 2000-08-07 | 2012-04-03 | Anamar Ab | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH537372A (de) * | 1968-01-22 | 1973-07-13 | Sandoz Ag | Verfahren zur Herstellung von 1-Amino-3-hydroxyguanidin |
| US3621056A (en) * | 1968-08-16 | 1971-11-16 | Sandoz Ag | Substituted benzylideneamino guanidines |
| US3857933A (en) * | 1969-10-17 | 1974-12-31 | Hoechst Ag | Process for the manufacture of a drug dosage form permitting controlled release of active ingredient |
-
1975
- 1975-09-22 FR FR7528940A patent/FR2324294A1/fr active Granted
-
1976
- 1976-09-10 IL IL50458A patent/IL50458A/xx unknown
- 1976-09-16 NL NL7610344A patent/NL7610344A/xx active Search and Examination
- 1976-09-17 DE DE2641988A patent/DE2641988C2/de not_active Expired
- 1976-09-21 GR GR51741A patent/GR63149B/el unknown
- 1976-09-21 GB GB39109/76A patent/GB1521594A/en not_active Expired
- 1976-09-21 IE IE2088/76A patent/IE44387B1/en unknown
- 1976-09-21 NZ NZ182128A patent/NZ182128A/xx unknown
- 1976-09-21 AU AU17963/76A patent/AU506061B2/en not_active Expired
- 1976-09-21 PT PT65618A patent/PT65618B/pt unknown
- 1976-09-21 BE BE170785A patent/BE846399A/xx not_active IP Right Cessation
- 1976-09-21 CA CA261,673A patent/CA1079195A/fr not_active Expired
- 1976-09-21 ZA ZA765640A patent/ZA765640B/xx unknown
- 1976-09-22 JP JP51113214A patent/JPS5241239A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8148429B2 (en) | 2000-08-07 | 2012-04-03 | Anamar Ab | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| US8309609B2 (en) | 2000-08-07 | 2012-11-13 | Anamar Ab | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| US8410174B2 (en) | 2000-08-07 | 2013-04-02 | Anamar Ab | Method for treating arthritis |
| US9227927B2 (en) | 2000-08-07 | 2016-01-05 | Anamar Ab | Method of treating inflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| GR63149B (en) | 1979-09-25 |
| GB1521594A (en) | 1978-08-16 |
| FR2324294B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1979-09-14 |
| AU1796376A (en) | 1978-04-06 |
| CA1079195A (fr) | 1980-06-10 |
| PT65618B (fr) | 1978-07-04 |
| IL50458A0 (en) | 1976-11-30 |
| IE44387L (en) | 1977-03-22 |
| AU506061B2 (en) | 1979-12-13 |
| BE846399A (fr) | 1977-03-21 |
| NZ182128A (en) | 1978-09-25 |
| FR2324294A1 (fr) | 1977-04-15 |
| NL7610344A (nl) | 1977-03-24 |
| IL50458A (en) | 1981-02-27 |
| JPS5241239A (en) | 1977-03-30 |
| DE2641988A1 (de) | 1977-03-24 |
| PT65618A (fr) | 1976-10-01 |
| ZA765640B (en) | 1977-10-26 |
| DE2641988C2 (de) | 1986-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU600950B2 (en) | Controlled release dihydrocodeine composition | |
| AU602375B2 (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain h1 and h2 receptor blockers | |
| KR940011246B1 (ko) | 로라타딘, 이부프로펜 및 슈도에페드린을 함유하는 약제학적 조성물 | |
| CA1267605A (en) | Pharmaceutical composition containing phenindamine | |
| US5037815A (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers | |
| HUE029035T2 (en) | Topical formulation for a jak inhibitor | |
| HUP0200549A2 (hu) | Apomorfint és szildenafilt tartalmazó készítmények és alkalmazásuk | |
| JPH05194227A (ja) | 薬 剤 | |
| JP2004508311A (ja) | 頭痛、片頭痛、悪心及び嘔吐用の医薬組成物 | |
| US6906049B1 (en) | Contraceptive medicine based on a progestational agent and an oestrogen and preparation method | |
| TWI224001B (en) | Single dose pharmaceutical composition of lasofoxifene for oral administration | |
| JP2003515531A (ja) | 新規なホルモン組成物とその利用 | |
| AU676032B2 (en) | Use of granisetron for the treatment of post-operative nausea and vomiting | |
| IE44387B1 (en) | Delayed-action hypotensive pharmaceutical compositions | |
| JP5420583B2 (ja) | プロピレングリコールおよびアルカン酸イソプロピルエステルを含む抗ウイルス製剤 | |
| US5049588A (en) | Novel treatment for ischemia using an aminotetralin | |
| JP2003503453A (ja) | 相乗作用組成物：ガバペンチンおよびプレガバリン | |
| JP2001097856A (ja) | 鎮咳剤 | |
| EP0190851A1 (en) | Improved antiinflammatory composition | |
| AU784478B2 (en) | Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same | |
| AU601007B2 (en) | The effect of a combination of a beta-adrenergic agonist and certain histamine h1-and/or h2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions | |
| GB2197198A (en) | Analgesic preparations | |
| JPH08501796A (ja) | イブプロフェン−カフェイン配合物 | |
| NZ314584A (en) | Antispasmodic composition containing a non steroidal anti inflammatory drug such as diclofenac or nimesulide, pitofenone hydrochloride and fenpiverinium bromide | |
| EP0868915A1 (en) | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium |